What's new in antibiotic resistance? Focus on beta-lactamases

被引:160
作者
Babic, Maja
Hujer, Andrea M.
Bonomo, Robert A.
机构
[1] Case Western Reserve Univ, Vet Affairs Med Ctr, Infect Dis Sect, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA
[3] Univ Hosp Cleveland, Dept Med, Div Infect Dis, Cleveland, OH 44106 USA
关键词
beta-lactamases; cephalosporinases; carbapenemases; extended-spectrum beta-lactamases; ESBLs;
D O I
10.1016/j.drup.2006.05.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In gram-negative bacteria, beta-lactamases are the most important mechanism of resistance to beta-lactam antibiotics. Currently, the beta-lactamases receiving the most attention are the extended-spectrum beta-lactamases (ESBLs), inhibitor-resistant beta-lactamases and carbapenemases. When found in Escherichia coli and Klebsiella spp., ESBLs confer resistance to extended-spectrum cephalosporins, such as ceftazidime, cefotaxime and cefepime. Hence, ESBLs limit the choice of beta-lactam therapy to carbapenems. A worrisome trend is the increasing number of pathogens found in isolates from patients in the community that possess ESBLs. It is equally distressing that carbapenemases (serine and metallo-beta-lactamases) are being found in many of the same bacteria that harbor ESBLs, for example Klebsiella pneumoniae. Despite many years studying beta-lactamases, important clinical and scientific questions still remain. Published by Elsevier Ltd.
引用
收藏
页码:142 / 156
页数:15
相关论文
共 140 条
  • [1] Kinetics study of KPC-3, a plasmid-encoded class a carbapenem-hydrolyzing β-lactamase
    Alba, J
    Ishii, Y
    Thomson, K
    Moland, ES
    Yamaguchi, K
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) : 4760 - 4762
  • [3] SHV-16, a β-lactamase with a pentapeptide duplication in the omega loop
    Arpin, C
    Labia, R
    Andre, C
    Frigo, CC
    El Harrif, Z
    Quentin, C
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (09) : 2480 - 2485
  • [4] Role of the 'cre/blr-tag' DNA sequence in regulation of gene expression by the Aeromonas hydrophila β-lactamase regulator, BlrA
    Avison, MB
    Niumsup, P
    Nurmahomed, K
    Walsh, TR
    Bennett, PM
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (02) : 197 - 202
  • [5] CHARACTERIZATION OF A NEW TEM-TYPE BETA-LACTAMASE RESISTANT TO CLAVULANATE, SULBACTAM, AND TAZOBACTAM IN A CLINICAL ISOLATE OF ESCHERICHIA-COLI
    BLAZQUEZ, J
    BAQUERO, MR
    CANTON, R
    ALOS, I
    BAQUERO, F
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (10) : 2059 - 2063
  • [6] Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin
    Bogdanovich, T
    Ednie, LM
    Shapiro, S
    Appelbaum, PC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (10) : 4210 - 4219
  • [7] Growing group of extended-spectrum β-lactamases:: The CTX-M enzymes
    Bonnet, R
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) : 1 - 14
  • [8] The antimicrobial armamentarium: Evaluating current and future treatment options
    Bosso, JA
    [J]. PHARMACOTHERAPY, 2005, 25 (10): : 55S - 62S
  • [9] Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City
    Bradford, PA
    Bratu, S
    Urban, C
    Visalli, M
    Mariano, N
    Landman, D
    Rahal, JJ
    Brooks, S
    Cebular, S
    Quale, J
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 39 (01) : 55 - 60
  • [10] Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY:: molecular epidemiology and in vitro activity of polymyxin B and other agents
    Bratu, S
    Tolaney, P
    Karumudi, U
    Quale, J
    Mooty, M
    Nichani, S
    Landman, D
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (01) : 128 - 132